Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 3.81B | 3.81B | 4.58B | 6.28B | 6.77B | 5.55B |
Gross Profit | 324.69M | 843.67M | 1.33B | 2.27B | 2.86B | 2.10B |
EBITDA | -620.17M | -662.07M | -2.69M | 893.14M | 1.65B | 1.19B |
Net Income | -1.35B | -1.35B | -469.30M | 255.65M | 898.59M | 650.49M |
Balance Sheet | ||||||
Total Assets | 8.81B | 8.81B | 9.75B | 9.79B | 8.97B | 6.78B |
Cash, Cash Equivalents and Short-Term Investments | 27.05M | 27.05M | 16.47M | 27.54M | 33.44M | 15.42M |
Total Debt | 5.55B | 5.55B | 4.94B | 3.41B | 2.79B | 1.87B |
Total Liabilities | 6.46B | 6.46B | 6.05B | 5.60B | 5.00B | 3.68B |
Stockholders Equity | 2.35B | 2.35B | 3.69B | 4.19B | 3.96B | 3.09B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -302.20M | -1.25B | -426.03M | -803.74M | -1.11B |
Operating Cash Flow | 0.00 | -83.99M | 102.21M | 746.56M | 236.04M | -81.62M |
Investing Cash Flow | 0.00 | -152.30M | -1.35B | -1.13B | -1.04B | -731.10M |
Financing Cash Flow | 0.00 | 237.33M | 1.25B | 377.70M | 804.77M | 813.36M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | ₹13.23B | 21.80 | 2.25% | -1.78% | 56.00% | ||
61 Neutral | $10.24B | 6.18 | 0.71% | 2.90% | 3.45% | -36.02% | |
60 Neutral | ₹26.64B | 25.36 | 0.86% | 2.73% | -11.40% | ||
56 Neutral | ₹14.13B | 30.99 | 0.26% | 9.24% | 2.10% | ||
52 Neutral | ₹14.10B | 459.40 | 0.36% | ― | ― | ||
45 Neutral | ₹19.53B | ― | 0.16% | 4.76% | -63.21% | ||
― | ₹10.81B | 3,871.25 | 0.32% | ― | ― |
Astec LifeSciences Limited announced the outcome of its Rights Issue Committee meeting held on July 29, 2025, where they approved the allotment of 26,69,951 equity shares on a rights basis to eligible shareholders at a price of ₹890 per share. This move increases the company’s paid-up equity share capital from 1,96,11,710 to 2,22,81,661 shares, potentially strengthening its financial position and market standing.
Astec LifeSciences Limited has published its unaudited financial results for the quarter ending June 30, 2025, as approved by its Board of Directors. The results were announced through newspaper advertisements in Business Standard and Mumbai Lakshdeep, reflecting the company’s commitment to transparency and regulatory compliance.
Astec LifeSciences Limited held its 31st Annual General Meeting (AGM) on July 28, 2025, via video conferencing, where key business matters were addressed. The meeting included the presentation of financial statements and audit reports, and shareholders were provided with electronic voting facilities. The results of the voting will be announced within two working days and made available on the company’s website, reflecting the company’s commitment to transparency and stakeholder engagement.
Astec LifeSciences Limited has announced the appointment of M/s. BNP & Associates as the secretarial auditors for a five-year term starting from the financial year 2025-26. This decision, approved at the company’s 31st Annual General Meeting, is expected to enhance the company’s compliance and governance standards, potentially strengthening its market position and stakeholder confidence.
Astec LifeSciences Limited announced the approval of its unaudited financial results for the quarter ended June 30, 2025, during a board meeting held on July 28, 2025. The results, which were reviewed by the statutory auditors and received an unmodified opinion, reflect the company’s adherence to Indian Accounting Standards (IND AS) and demonstrate its commitment to transparency and regulatory compliance. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance for the specified period.